Welcome, Guest. Please login or register.
November 28, 2021, 10:59:00 pm

Login with username, password and session length


  • Total Posts: 327
  • Total Topics: 183
  • Online Today: 32
  • Online Ever: 518
  • (January 21, 2020, 05:24:49 pm)
Users Online
Users: 0
Guests: 10
Total: 10


Welcome to the Cancer Health Forums, a round-the-clock discussion area for people who have any type of cancer, their friends and family and others with questions about living with cancer. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Cancer Health Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Why do so few people benefit from “breakthrough” cancer immunotherapy?  (Read 1469 times)

Offline danialthomas

  • Jr. Member
  • **
  • Posts: 51
  • Doctor Of Osteopathy
    • View Profile
    • Thomas Health Blog
When the first immunotherapy drug ipilimumab (Yervoy) was FDA approved in 2011, immunotherapy was hailed as breakthrough in cancer treatment. This new therapy harnessed the power of the body’s own immune system to fight cancer. Fast forward to today and, unfortunately, only a minority of cancer patients actually benefit from immunotherapy in terms of tumor shrinkage, and even fewer experience long-term survival.
Why did immunotherapy not live up to the hype? It turns out that simply “revving up” the immune system is not enough. Having plenty of natural-killer (NK) cells, cytotoxic T-cells (CTCs), and M1 macrophages is insufficient. Tumors still have ways to avoid immune destruction which include:

• Recruitment of immunosuppressive T-regulatory cells (Tregs) and myeloid cells.
• Recruitment of tumor-killing M1 macrophages and polarizing them into tumor-promoting M2 macrophages (also known as tumor-associated macrophages or TAMs).
• Malignant cell exposure to blood platelets.
• Iron-induced parafibrin formation blocking immune-mediated destruction.
• Tumor collagen density preventing adequate infiltration of immune cells.
• Lack of sufficient energy by immune cells.
To improve the efficacy of immunotherapy, it is important to:
• Reduce Tregs and myeloid cells using ivermectin.
• Repolarize tumor-promoting M2 macrophages into tumor-killing M1 macrophages using onionin A, a sulfur-containing compound from onions.
• Reduce platelet aggregation and reduce tumor density using pentoxifylline (Trental).
• Block formation of parafibrin using curcumin, EGCG, ferulic acid, magnesium, and sodium selenite.
• Supplement with creatine. Creatine, a supplement that is popular with athletes and bodybuilders, serves as a “molecular battery” for immune cells by storing and distributing energy to power their fight against cancer.

Please note that this information for educational purposes only. It is not intended or implied to be a substitute for professional medical advice, diagnosis, treatment, and monitoring by your personal physician. Therefore, I cannot give dosages for the above-mentioned supplements and medications. That is for your personal physician to determine.

Dr. Daniel Thomas, DO, MS
Mount Dora, Florida

Bałan BJ, Demkow U, Skopiński P, et al. The effect of pentoxifylline on L-1 sarcoma tumor growth and angiogenesis in Balb/c mice. Cent Eur J Immunol. 2017;42(2):131-139.
Draganov D, Han Z, Rana A, Bennett N, Irvine DJ, Lee PP. Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer. NPJ Breast Cancer. 2021 Mar 2;7(1):22.
Kim JH, Shin BC, Park WS, Lee J, Kuh HJ. Antifibrotic effects of pentoxifylline improve the efficacy of gemcitabine in human pancreatic tumor xenografts. Cancer Sci. 2017 Dec;108(12):2470-2477.
Lipinski B. Iron-induced parafibrin formation in tumors fosters immune evasion.
Stefano Di Biase, Xiaoya Ma, Xi Wang, Jiaji Yu, Yu-Chen Wang, Drake J. Smith, Yang Zhou, Zhe Li, Yu Jeong Kim, Nicole Clarke, Angela To, Lili Yang; Creatine uptake regulates CD8 T cell antitumor immunity. J Exp Med 2 December 2019; 216 (12): 2869–2882.
Tsuboki, J., Fujiwara, Y., Horlad, H. et al. Onionin A inhibits ovarian cancer pro-gression by suppressing cancer cell proliferation and the protumour function of macrophages. Sci Rep 6, 29588 (2016).
Located in Mount Dora, Florida, Dr. Thomas is one of the most educated, experienced, and innovative physicians in North America. Over the past 30 years, he has helped people throughout the United States and Canada to prevent and overcome disease, improve their health, slow aging, and increase their lifespan. As an active translational researcher, Dr. Thomas has spent over 35,000 hours poring over the latest scientific discoveries and translating max. discoveries into promising theories


© 2021 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.